Inhibikase Therapeutics Stock Analysis
IKT Stock | USD 2.30 0.04 1.71% |
Inhibikase Therapeutics is undervalued with Real Value of 3.45 and Target Price of 7.0. The main objective of Inhibikase Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Inhibikase Therapeutics is worth, separate from its market price. There are two main types of Inhibikase Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Inhibikase Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Inhibikase Therapeutics is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day. Inhibikase Stock trading window is adjusted to America/New York timezone.
Inhibikase |
Inhibikase Stock Analysis Notes
About 12.0% of the company shares are held by company insiders. The company recorded a loss per share of 3.12. Inhibikase Therapeutics had not issued any dividends in recent years. The entity had 1:6 split on the 30th of June 2023. Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinsons Disease and related disorders that arise inside and outside of the brain. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia. Inhibikase Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 6 people. To learn more about Inhibikase Therapeutics call the company at 678 392 3419 or check out https://www.inhibikase.com.Inhibikase Therapeutics Investment Alerts
Inhibikase Therapeutics had very high historical volatility over the last 90 days | |
Inhibikase Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
The company reported the last year's revenue of 260.5 K. Reported Net Loss for the year was (19.03 M) with loss before taxes, overhead, and interest of (13.02 M). | |
Inhibikase Therapeutics has about 32.21 M in cash with (18.09 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.28. | |
Inhibikase Therapeutics has a poor financial position based on the latest SEC disclosures | |
Over 76.0% of the company shares are owned by institutional investors | |
Latest headline from gurufocus.com: Inhibikase Announces Expansion of Senior Leadership Team |
Inhibikase Therapeutics Upcoming and Recent Events
29th of March 2024 Upcoming Quarterly Report | View | |
20th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
29th of March 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Inhibikase Largest EPS Surprises
Earnings surprises can significantly impact Inhibikase Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2023-05-15 | 2023-03-31 | -0.14 | -0.16 | -0.02 | 14 | ||
2022-03-31 | 2021-12-31 | -0.17 | -0.2 | -0.03 | 17 | ||
2021-11-15 | 2021-09-30 | -0.14 | -0.18 | -0.04 | 28 |
Inhibikase Therapeutics Environmental, Social, and Governance (ESG) Scores
Inhibikase Therapeutics' ESG score is a quantitative measure that evaluates Inhibikase Therapeutics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Inhibikase Therapeutics' operations that may have significant financial implications and affect Inhibikase Therapeutics' stock price as well as guide investors towards more socially responsible investments.
Inhibikase Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Millennium Management Llc | 2024-12-31 | 142.2 K | Blair William & Co | 2024-12-31 | 135 K | Barclays Plc | 2024-12-31 | 84 K | Citigroup Inc | 2024-12-31 | 77.1 K | Northern Trust Corp | 2024-12-31 | 64 K | Omers Administration Corp | 2024-12-31 | 54.6 K | Hrt Financial Llc | 2024-12-31 | 46.4 K | Goldman Sachs Group Inc | 2024-12-31 | 44 K | State Street Corp | 2024-12-31 | 41.9 K | Sands Capital Ventures, Llc | 2024-12-31 | 10.9 M | Soleus Capital Management, L.p. | 2024-12-31 | 6.3 M |
Inhibikase Market Capitalization
The company currently falls under 'Small-Cap' category with a total capitalization of 167.17 M.Inhibikase Profitablity
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (1.18) | (1.24) | |
Return On Capital Employed | (2.09) | (1.98) | |
Return On Assets | (1.18) | (1.24) | |
Return On Equity | (1.99) | (1.89) |
Management Efficiency
Inhibikase Therapeutics has Return on Asset of (1.1268) % which means that on every $100 spent on assets, it lost $1.1268. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (2.701) %, meaning that it generated no profit with money invested by stockholders. Inhibikase Therapeutics' management efficiency ratios could be used to measure how well Inhibikase Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.24 in 2025. Return On Capital Employed is likely to gain to -1.98 in 2025. Liabilities And Stockholders Equity is likely to gain to about 18.3 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 3.7 M in 2025.Last Reported | Projected for Next Year | ||
Book Value Per Share | 1.85 | 2.05 | |
Tangible Book Value Per Share | 1.85 | 2.05 | |
Enterprise Value Over EBITDA | 0.08 | 0.08 | |
Price Book Value Ratio | 0.56 | 0.58 | |
Enterprise Value Multiple | 0.08 | 0.08 | |
Price Fair Value | 0.56 | 0.58 | |
Enterprise Value | -2 M | -1.9 M |
Understanding the management dynamics of Inhibikase Therapeutics allows us to gauge its ability to sustain growth and profitability. This comprehensive analysis aids in determining the stock's value.
Technical Drivers
As of the 1st of March, Inhibikase Therapeutics retains the Downside Deviation of 8.62, risk adjusted performance of 0.0581, and Market Risk Adjusted Performance of (0.30). Inhibikase Therapeutics technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.Inhibikase Therapeutics Price Movement Analysis
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Inhibikase Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Inhibikase Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Inhibikase Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Inhibikase Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Inhibikase Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Inhibikase Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Inhibikase Therapeutics Outstanding Bonds
Inhibikase Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Inhibikase Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Inhibikase bonds can be classified according to their maturity, which is the date when Inhibikase Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Dana 575 percent Corp BondUS235822AB96 | View | |
MPLX LP 4125 Corp BondUS55336VAK61 | View | |
MPLX LP 52 Corp BondUS55336VAL45 | View | |
INGREDION INC 32 Corp BondUS457187AB87 | View | |
US457187AC60 Corp BondUS457187AC60 | View | |
US457187AD44 Corp BondUS457187AD44 | View | |
Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
MGM Resorts International Corp BondUS552953CD18 | View |
Inhibikase Therapeutics Predictive Daily Indicators
Inhibikase Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Inhibikase Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Accumulation Distribution | 39835.37 | |||
Daily Balance Of Power | (0.13) | |||
Rate Of Daily Change | 0.98 | |||
Day Median Price | 2.38 | |||
Day Typical Price | 2.36 | |||
Price Action Indicator | (0.11) | |||
Period Momentum Indicator | (0.04) |
Inhibikase Therapeutics Corporate Filings
F3 | 25th of February 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
8K | 24th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 19th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 18th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
14th of February 2025 Other Reports | ViewVerify | |
4th of February 2025 Other Reports | ViewVerify | |
8K | 29th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 22nd of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Inhibikase Therapeutics Forecast Models
Inhibikase Therapeutics' time-series forecasting models are one of many Inhibikase Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Inhibikase Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Inhibikase Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Inhibikase Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Inhibikase shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Inhibikase Therapeutics. By using and applying Inhibikase Stock analysis, traders can create a robust methodology for identifying Inhibikase entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | (84.00) | (79.80) | |
Operating Profit Margin | (88.69) | (84.25) | |
Net Loss | (84.00) | (79.80) | |
Gross Profit Margin | (58.97) | (56.02) |
Current Inhibikase Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Inhibikase analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Inhibikase analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
7.0 | Strong Buy | 3 | Odds |
Most Inhibikase analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Inhibikase stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Inhibikase Therapeutics, talking to its executives and customers, or listening to Inhibikase conference calls.
Inhibikase Stock Analysis Indicators
Inhibikase Therapeutics stock analysis indicators help investors evaluate how Inhibikase Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Inhibikase Therapeutics shares will generate the highest return on investment. By understating and applying Inhibikase Therapeutics stock analysis, traders can identify Inhibikase Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow | 7.2 M | |
Common Stock Shares Outstanding | 5.3 M | |
Total Stockholder Equity | 11 M | |
Property Plant And Equipment Net | 295.6 K | |
Cash And Short Term Investments | 13.3 M | |
Cash | 9.2 M | |
Accounts Payable | 646.8 K | |
Net Debt | -8.5 M | |
50 Day M A | 2.8064 | |
Total Current Liabilities | 3.4 M | |
Other Operating Expenses | 20.4 M | |
Non Current Assets Total | 295.6 K | |
Non Currrent Assets Other | 15.8 M | |
Stock Based Compensation | 500.1 K |
Additional Tools for Inhibikase Stock Analysis
When running Inhibikase Therapeutics' price analysis, check to measure Inhibikase Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibikase Therapeutics is operating at the current time. Most of Inhibikase Therapeutics' value examination focuses on studying past and present price action to predict the probability of Inhibikase Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibikase Therapeutics' price. Additionally, you may evaluate how the addition of Inhibikase Therapeutics to your portfolios can decrease your overall portfolio volatility.